Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530 | See remarks | May 20, 2025 | May 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ginkgo Bioworks Holdings, Inc.
Report date May 20, 2025 · Filed May 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 46,226 |
Ending reported balance
After 2025-05-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-05-20 · Exercise / conversion · Acquired 454 · Balance 45,907 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 2 · 2025-05-20 · Exercise / conversion · Acquired 453 · Balance 46,360 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 3 · 2025-05-20 · Exercise / conversion · Acquired 572 · Balance 46,932 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 4 · 2025-05-21 · Sale · Disposed 706 · Balance 46,226 F2: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,614 |
Reported balance
After 2025-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-20 · Exercise / conversion · Disposed 454 · Balance 3,614 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,970 |
Reported balance
After 2025-05-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-20 · Exercise / conversion · Disposed 453 · Balance 9,970 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 19,488 |
Reported balance
After 2025-05-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-20 · Exercise / conversion · Disposed 572 · Balance 19,488 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: The RSUs vest in 48 equal monthly installments, which began on April 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F3: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.
F4: The RSUs vest in 48 equal monthly installments, which began on April 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2022 Filed Jan 26, 2022 18:44 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003310 · doc4.xml · derivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Class B Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock. F2 · derivative.exercise_date: 2. The RSUs vest as follows: 5% of the underlying shares on January 1, 2023; 12 monthly installments of 0.83% of the underlying shares thereafter; 12 monthly installments of 1.25% of the underlying shares thereafter; 24 monthly installments of 1.67% of the underlying shares thereafter; and 12 monthly installments of 2.5% of the underlying shares thereafter. F2 · derivative.expiration_date: 2. The RSUs vest as follows: 5% of the underlying shares on January 1, 2023; 12 monthly installments of 0.83% of the underlying shares thereafter; 12 monthly installments of 1.25% of the underlying shares thereafter; 24 monthly installments of 1.67% of the underlying shares thereafter; and 12 monthly installments of 2.5% of the underlying shares thereafter. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:47 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantClass B Common Stock · Derivative | 314,097 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036681 · doc4.xml · derivative · entry 1 Dmytruk Mark E. · CIK 0001873507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,097 Underlying: Class A Common Stock · 314,097 shares Expires not disclosed F1 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · price: Pursuant to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. ("Legacy Ginkgo"), as contemplated by an agreement and plan of merger, dated May 11, 2021 as amended on May 14, 2021 (the "Merger Agreement"), each share of Class A common stock of Legacy Ginkgo, each share of Class B common stock of Legacy Ginkgo, each option of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, each award of restricted common stock of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, and each award of restricted stock units of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, in each case outstanding immediately prior to the effective time of the business combination, received a proportional amount of the approximately 188.7 million earn-out shares. F1 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · balance_after: Reflects earn-out shares that will vest in four substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $12.50, $15.00, $17.50 and $20.00. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.